Watchlist Price Alert

Orchestra BioMed Inc. (OBIO)

NASDAQ: OBIO · Real-Time Price · USD

3.05

-0.21 (-6.44%)

At close: Jun 05, 2025, 3:59 PM

3.18

4.26%

After-hours: Jun 05, 2025, 05:39 PM EDT

-6.44% (1D)

Bid	3
Market Cap	116.85M
Revenue (ttm)	2.89M
Net Income (ttm)	-66.32M
EPS (ttm)	-1.77
PE Ratio (ttm)	-1.72
Forward PE	-1.84
Analyst	Buy

Ask	3.45
Volume	224,240
Avg. Volume (20D)	382,853
Open	3.24
Previous Close	3.26
Day's Range	3.05 - 3.27
52-Week Range	2.37 - 8.87
Beta	0.63

About OBIO

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol OBIO

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for OBIO stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

3 weeks ago

+10.94%

Orchestra BioMed shares are trading higher after t... Unlock content with Pro Subscription

1 month ago

+0.7%

Orchestra BioMed shares are trading higher after the company announced it secured FDA Breakthrough Device Designation for AVIM therapy.

News

1 week ago · seekingalpha.com

Orchestra BioMed: Two Best-In-Class Devices And Promising Partnerships

Orchestra BioMed holds two best-in-class medical device therapies targeting large markets, with strong partnerships and equity investments from Medtronic and Terumo. Both AVIM Therapy and Virtue SAB h...

3 weeks ago · zacks.com

Orchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Tops Revenue Estimates

Orchestra BioMed Holdings, Inc. (OBIO) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.46. This compares to loss of $0.38 per share a year ago.

1 month ago · zacks.com

Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Orchestra BioMed Holdings, Inc. (OBIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago · zacks.com

Orchestra BioMed Holdings, Inc. (OBIO) Reports Q4 Loss, Lags Revenue Estimates

Orchestra BioMed Holdings, Inc. (OBIO) came out with a quarterly loss of $0.43 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.37 per share a year ago.